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Background: Recent advances in magnetic resonance imaging make it possible to visualize the presumed
pathophysiologic correlate of Menière’s disease: endolymphatic hydrops. As traditional diagnostic tests can provide
only indirect evidence, they are hardly competitive in this respect and need to be rethought. This is done here for
the glycerol test.
Methods: The data of a previous retrospective analysis of the glycerol test in patients with suspected Menière’s
disease are reinterpreted using a simple model. The mean threshold reduction (MTR) in the frequency range from
125 to 1500 Hz (calculated from audiograms obtained immediately before and four hours after the glycerol intake)
is used as the test statistic. The proposed model explains the frequency distribution of the observed MTR by the
convolution of a Gaussian probability density function (representing measurement errors) with a template
representing the frequency distribution of the true MTR. The latter is defined in terms of two adjustable parameters.
After fitting the model to the data, the performance of the test is evaluated using receiver operating characteristic
(ROC) analysis.
Results: The cumulative frequency distribution of the observed MTR can be explained almost perfectly by the
model. According to the ROC analysis performed, the capability of the currently used audiometric procedure to
detect a glycerol-induced threshold reduction corresponds to a diagnostic test of rather high accuracy (area under
the ROC curve greater than 0.9). Simulations show that methodological improvements could further enhance the
performance.
Conclusions: Owing to their ability to reveal functional aspects without an obvious morphological correlate,
traditional test for Menière’s disease could be decisive for defining the stage of the disease. A distinctive feature of
the glycerol test is that it is capable of determining, with high accuracy, whether the pathophysiologic condition of
the inner ear is partially reversible. Prospectively, this could help to estimate the chances of specific therapies.Background
In 1861, Prosper Menière reported on patients who
suddenly suffered from intermittent attacks of vertigo
combined with tinnitus and a gradually increasing hearing
loss [1]. Although more than 150 years have passed since
then, the disease, now named after him, is still not fully
understood, and the criteria for establishing the diagnosis
have not fundamentally changed. According to the widely
accepted guidelines of the Committee on Hearing and
Equilibrium of the American Academy of Otolaryngology -
Head and Neck Surgery [2], the diagnosis of definite
Menière’ disease requires (1) two or more definitive* Correspondence: Lutkenh@uni-muenster.de
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article, unless otherwise stated.spontaneous episodes of vertigo 20 minutes or longer,
(2) an audiometrically documented hearing loss on at
least one occasion, (3) tinnitus or aural fullness in the
treated ear, and (4) the exclusion of other causes; prob-
able Menière’ disease is diagnosed if there is only one
definite episode of vertigo. These definitions show
that, as yet, the identification of Menière’s disease is
largely dependent on the patient’s medical history. By
implication this means that the numerous efforts to
develop a specific diagnostic test [3,4] did not lead to a
practice that gained general acceptance. Recently, how-
ever, a major breakthrough was achieved. Using magnetic
resonance imaging (MRI) with gadolinium as the contrast
agent, Nakashima et al. [5] succeeded to visualize the
presumed pathophysiologic correlate of Menière’s disease:ed Central Ltd. This is an Open Access article distributed under the terms of the
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guidelines, the diagnosis of definite Menière’s disease be-
comes certain by such confirmation, which hitherto could
be obtained only after death. Meanwhile, this seminal work
has been confirmed in many subsequent studies, in which
the methodology was not only improved [6,7], but also ap-
plied to specific questions [8-11].
In an MRI study by Fiorino et al. [12], each of 26
patients diagnosed with definite Menière’s disease showed
evidence of endolymphatic hydrops exclusively in the
affected ear. Moreover, there was no such evidence in 11
of 12 patients with other inner ear diseases. Considering
the conclusiveness of these results, it can be expected that
MRI will soon be the method of choice if a suspected
diagnosis of Menière’s disease is to be confirmed by
proving the hydrops. This intriguing progress appears to
eliminate the need for other diagnostic procedures.
However, such a conclusion would be premature. Diag-
nostic tests should be appraised in terms of their ability
to improve patient-important outcomes [13], and in this
respect, some of the traditional methods (or a combin-
ation of them) may ultimately turn out to be competitive,
especially since it is not clear how important it is to prove
endolymphatic hydrops in patients that were already
diagnosed with definite Menière’s disease. If the above-
mentioned results are representative, meaning that pa-
tients so diagnosed nearly always have endolymphatic
hydrops (a supposition that would be consistent with
Merchant et al. [14]), verifying the hydrops by whatever
method provides hardly any new information. Thus, in
future, more emphasis should probably be placed on the
question as to what the various diagnostic tests can tell
us about the stage and manifestation of the disease and
to what extent they allow us to predict the prospects of
specific therapeutic measures, e.g., treatment with beta-
histine [15].
As proving endolymphatic hydrops appears to become
the domain of imaging techniques, the possible future
roles of other diagnostic tests for Menière’s disease need
to be rethought. This is done here for the glycerol test
devised by Klockhoff and Lindblom [16], but some basic
conclusions appear to be valid for other diagnostic proce-
dures as well. The test exploits the fact that, in patients
suffering from Menière’s disease, oral application of gly-
cerol can temporarily improve the threshold of hearing,
whereas no systematic effect is to be expected in patients
with other hearing disorders and subjects with normal
hearing. The underlying idea is that the dehydrating effect
of glycerol transiently reduces the endolymphatic volume,
which in turn may lead to partial recovery from hearing
loss. To test for the latter, a pre-test audiogram is com-
pared with an audiogram taken a few hours after the gly-
cerol intake. While a significant threshold reduction can
be regarded as evidence of endolymphatic hydrops, thereverse is not true: Since Menière’s disease is typically
fluctuating and progressive [17,18], there may be
hydrops despite a negative glycerol test. It is known,
for example, that the probability of a positive glycerol test
depends on the phase of the disease, being minimal at
times of remission [19]. Moreover, the hearing loss may be
irreversible at a more advanced stage so that reducing the
endolymphatic volume has no effect anymore.
Several variants of the glycerol test have been proposed
since its first description, and so it seems timely to
scrutinize the conceptual and methodological details of
the test. In a previous article [20], we presented a retro-
spective study of 356 cases with suspected Menière’s
disease (all ears fulfilled the aforementioned criteria for
definite or at least probable Menière’s disease). In
addition to descriptive analyses of the data, we introduced
a new criterion for a positive test result. Moreover, we
proposed a rule of thumb that can be used to define a sub-
population of patients for whom the probability of a posi-
tive outcome is significantly higher than for the excluded
patients. The rule proved to be competitive with more ad-
vanced predictive modeling approaches [21]. However,
gaining a deeper understanding of the test was impeded
by the fact that there is no “gold standard” to compare
with and that the determination of the auditory threshold
is, like any measurement, affected by errors. In the present
work, these problems are overcome by fitting a simple
model to the data. The model gives an idea of what the re-
sults would be if the thresholds of hearing were deter-
mined exactly. Moreover, it becomes possible to assess the
performance of the test by considering its receiver operat-
ing characteristic (ROC) curve and to predict what would
be gained by methodological amendments.
Methods
Data
The same data as in our previous study [20], now available
from a Digital Repository [22], are used. Briefly, archived
audiograms from 347 patients that underwent a glycerol
test to confirm a suspected Menière’s disease were tran-
scribed into a computer-readable form. The tests had been
performed following the protocol suggested by Klockhoff
[19], which means that glycerol (1.2 ml/kg body weight)
was orally administered with an equal amount of isotonic
saline solution. The audiograms were obtained immedi-
ately before the glycerol intake (pre-test audiogram) and
at hourly intervals thereafter (the last one obtained after
four hours). Since both ears were investigated in a few pa-
tients, 356 cases are available altogether. But to restrict
the data range to be plotted, two cases are excluded here
as outliers (apart from that, the exclusion has no relevant
impact on the results).
The effect of the administered glycerol is assessed by
comparing the pre-test audiogram with the audiogram
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[20], the aggregate threshold reduction (ATR) in a con-
tiguous frequency range was used as a summary measure.
But this quantity is inconvenient for modeling, because its
calculation requires to integrate over a variable frequency
range (the bounds of integration depend on the true hear-
ing losses at the different frequencies as well as measure-
ment errors), which makes it difficult (if not impossible)
to apply standard statistical techniques. Therefore an
alternative summary measure is used here: the mean
threshold reduction (MTR) at the five lowest audiometric
frequencies (125, 250, 500, 1000, and 1500 Hz), which rep-
resent the frequency range where the effect of glycerol is
typically most pronounced. A convenient side-benefit of
focusing on these frequencies is that the MTR is always
an integer number (five thresholds are averaged, each of
which was determined in steps of 5 dB).
Figure 1 shows that MTR (abscissa) and ATR (ordinate)
are highly correlated (R = 0.924). In principle, each of the
354 cases considered in this study is represented by a sin-
gle point, but the points partially coincide. Thus, instead



























Figure 1 Correlation between mean threshold reduction (MTR) and a
assume only a limited number of values. As a consequence, there are gene
that a standard scatter plot would be problematic. The problem was solved
radius so that the area of the circle is proportional to the number of occurren
criteria that generally lead to consistent decisions as to the presence of a glyc
indicates that the MTR is equal to or greater than the associated criterion valu
that the situation is just the other way round.number of points sharing the respective location are plot-
ted. If the criterion for a positive glycerol test is that the
ATR is at least 30 dB (dotted horizontal line), the false-
positive rate may be expected to be about 5% [20]. Con-
sistent decisions would be made by requiring the MTR to
be at least 5 dB (dotted vertical line), apart from the few
cases represented by the filled circles: In 16 cases (red
circles) the test would be positive only according to the
ATR-based criterion, and in 9 cases (blue circles) it would
be positive only according to the MTR-based criterion.
Convolution model
Audiograms measured at different times typically show
discrepancies even when there is no reason to assume
that the true threshold of hearing has changed. This intrin-
sic uncertainty of the threshold estimation may be consid-
ered as a measurement error, which, of course, propagates
to every audiogram-based measure. As a consequence, the
distribution of the observed MTR values reflects, to a
considerable extent, the measurement error rather than
the glycerol-induced threshold reduction. If the meas-
urement error is assumed to be additive to the glycerol10 15 20 25 30
d Reduction  (dB)
ggregate threshold reduction (ATR). Both the MTR and the ATR can
rally multiple occurrences for each combination of these measures so
by plotting a circle for each MTR-ATR combination and adjusting the
ces. The two dotted lines (one horizontal, the other vertical) represent
erol induced effect. The few exceptions are marked by filled circles: Blue
e while the ATR falls short of the corresponding threshold. Red indicates

































Figure 2 Model for the distribution of the “true” MTR (i.e., the
MTR that would be obtained if thresholds were estimated
without errors). (a) Basic idea. A first model parameter corresponds
to the proportion of patients without a glycerol-induced threshold
reduction (represented by the arrow), whereas a second one scales the
MTR distribution of the patients showing an effect. (b) Discretized and
smoothed version of the upper model.
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formula,
f xð Þ ¼
Z∞
−∞
g uð Þ h x−uð Þ du; ð1Þ
where f(x), g(x), and h(x) are probability density functions.
The first one, f(x), characterizes the distribution of the
MTR values actually observed, whereas the second one,
g(x), characterizes the distribution that would be observed
under ideal conditions, i.e., in the absence of measurement
errors. The third function, finally, is the probability density
function of the measurement error. In what follows, the
measurement error will be assumed to be normally distrib-
uted, with a standard deviation estimated from the data.
Given h(x), the unknown g(x) could be calculated by decon-
volving the observed f(x), at least in theory. However, to be
able to use this approach for the problem at hand, the
number of cases would have to be increased by at least an
order of magnitude [23,24]. Thus, Eq. (1) will be used here
in a different way. The idea is to “guess” a suitable function
g(x) and to determine the parameters of this function so
that the right-hand side of the equation optimally explains
the observed f(x).
As will be shown, the data can be explained reasonably
well by means of an empirical function g(x) depending
on only two parameters. The basic idea is outlined in
Figure 2a. Conceptually, the patients are divided into two
groups. Patients belonging to the first group, represented
by the arrow in the figure, are assumed to show no
glycerol-induced effect at all. Their proportion is denoted
as p0 (in Figure 2 having a value of 0.3). Patients belonging
to the second group are assumed to have a threshold reduc-
tion that is distributed according to a gamma distribution
with a shape parameter of 2 (the choice of this well-known
distribution was a pragmatic decision; other distributions
with similar properties could be assumed as well). The cor-
responding probability density function is, for x ≥ 0,
g2 xð Þ ¼ θ−2x exp −θ−1x
 
; ð2Þ
where θ is called the scale parameter. Figure 2a shows this
function for θ = 3. For reasons that will be explicated in
the Discussion (in essence, the goal is to avoid eye-
catching details that cannot be validated against the
data), this initial concept of function g(x) is modified as
follows. In a first step, function g2(x) is replaced by a
function that is constant between x = 0 and the maximum
at x = θ (indicated by the dashed line in Figure 2a).
Renormalization (to get a probability density function
again) yields:
~g 2 xð Þ ¼
1
3θ
1 f or 0 ≤ x≤ θ
θ−1x exp 1−θ−1x
 
f or x > θ

ð3ÞIn the next step, the distribution is discretized, taking
into account that the MTR is an integer. Cases with an
MTR not greater than 1 dB are finally combined with
those showing no effect, and the resulting no-effect
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and 1 dB (Figure 2b). The last step has no other purpose
than to facilitate the visualization of the model parameter
p0 (which otherwise would be represented by a rather high
peak).
Modeling investigator bias
A deviation of the observed error distribution from a
normal distribution will be interpreted as possible evidence
of a partially biased practice on the part of the investigator.
To corroborate the hypothesis, some modifications are ap-
plied to the above model. For a start, we confine ourselves
to considering the threshold estimation for a single fre-
quency. To mimic the common practice in clinical audi-
ometry, the real-valued measurement error (normally
distributed) is rounded to the nearest integer divisible
by 5. Bias is introduced by assuming that an investigator
sometimes reuses a previously estimated threshold instead
of taking the time to carefully measure a small threshold
change. To mimic this behavior in the model, a threshold
difference of 5 dB between previous and current audiogram
is ignored with a certain probability. Correspondingly, the
model provides for the possibility that an investigator oc-
casionally determines a threshold difference of 5 dB when
a more careful procedure would have resulted in a thresh-
old difference of 10 dB. It should be emphasized that the
investigator is assumed to be unprejudiced as to the sign
of the threshold change.
To simulate the estimation of MTRs, it was assumed
that threshold estimations at different times (and possibly
for different frequencies) have statistically independent
measurement errors with identical standard deviations,
σ. The difference between two threshold estimations
for the same frequency (test-retest reliability), then,
has the standard deviation 21/2σ, and averaging 5 such
differences (as required for obtaining the MTR) yields
a measure with the standard deviation (2/5)1/2σ. The
test-retest reliability of auditory threshold estimations
has been investigated in many studies [25-29], and un-
like in our model, the measurement error was found to
be frequency-dependent. But this does not seriously
compromise the validity of the model, because σ2 can
be understood as the mean variance for the frequencies
considered.
Numerical calculations
All calculations were done with custom scripts using
Matlab Version 7.14 (The MathWorks, Inc., Natick,
MA, USA). The model parameters were optimized by
least-squares fitting using the function FMINSEARCH
(considering the cumulative distribution functions).
ROC curves were calculated using the function PERF-
CURVE, which readily provides also the area under the
curve (AUC).The Monte Carlo simulations for the ROC analysis were
done as follows. First, “true” MTR values were assigned
to each of 100,000 cases so that the resulting cumulative
distribution function was in accordance with that of the
assumed model. Adding normally distributed random
numbers to these values then yielded the “experimen-
tally observed” MTR values.
Results
Measurement error
Before attempts can be made to correct the distribution
of observed threshold reductions for the measurement
error, the latter has to be characterized. Our previous
investigation (see Figure Four in [20]) suggested that the
effect of glycerol barely intensifies after the third hour.
Thus, the MTR distribution derived from the audiograms
taken three and four hours after the glycerol intake (histo-
gram on the left of Figure 3) is basically a fingerprint of
the measurement error. Mean and standard deviation
were calculated to be 0.26 dB and 2.45 dB, respectively
(the curve superimposed on the histogram shows a nor-
mal distribution with a standard deviation corresponding
to the calculated one, but with mean zero). The estimated
mean confirms the previous observation that the thresh-
old after 4 hours is only marginally lower than after
3 hours. The difference reached statistical significance,
though (two-sided t-test yielded P = 0.045).
A remarkable feature of the estimated distribution is
the pronounced peak at an MTR of zero, which is not
fully compatible with the idea of a normally distributed
measurement error. Although the reasons could be
manifold, a Monte Carlo simulation using the model
described in the Methods corroborates the hypothesis that
this peculiarity reflects a methodological shortcoming:
Knowledge of a previous audiogram biases the decision-
making on part of the investigator. To obtain the histo-
gram on the right of Figure 3, 100,000 partially biased
investigations were simulated. A comparison with the
histogram on the left shows that, by carefully adjusting
the parameters, an excellent agreement between model
and data could be achieved: It was assumed that single
threshold estimations have a standard deviation of σ = 4.43
dB, that a threshold difference of 5 dB between previous
and current audiogram is ignored in 80% of the cases, and
that a threshold difference of 10 dB is reduced to 5 dB in
30% of the cases. Again, the solid curve represents a zero-
mean normal distribution with a standard deviation corre-
sponding to that estimated from the data (the simulated
ones in this case). The dotted curve, by contrast, repre-
sents the distribution that, according to the model, would
be obtained in the case of an unbiased estimation (as
described in the Methods section, the standard deviation
assumed for single threshold estimations, σ, was converted


















Mean Threshold Reduction (dB)
Model
Figure 3 Analysis of the measurement error. The histogram on the left shows the MTR distribution estimated from the data, whereas the
histogram on the right is based on a Monte Carlo simulation in which the investigator was assumed to be partially biased. The superimposed
solid curves show normal distributions with zero mean and standard deviations corresponding to those calculated from the (measured or
simulated) data. The normal distribution shown as a dotted curve in the right panel refers to the measurement error in the unbiased model.
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illustrates that greater threshold changes are slightly
underrepresented in the latter.
Frequency distribution of the mean threshold reduction
For clinical testing, the audiogram obtained 4 hours after
the glycerol intake is compared with the pre-test audio-
gram rather than the audiogram obtained after three
hours (as in the error analysis above). The frequency dis-
tribution of the MTR calculated from these two audio-
grams is shown in the middle of Figure 4 (histogram).
The three rows represent different groups of patients. In
the upper row (a), all patients are considered, whereas
the other two rows represent subsets of patients who
either do (c) or do not (b) fulfill the rule of thumb pro-
posed in our previous article [20]. According to this rule,
the probability of a positive outcome of the glycerol test
is increased if the mean low-frequency hearing loss in
the pretest audiogram is within the range 30 to 70 dB
and not smaller than the mean high-frequency hearing
loss. Patients for whom the rule is satisfied will be referred
to as the good candidates; the others will be referred to as
the poor candidates, for the sake of convenience. Consist-
ent with this idea, large MTR values (>15 dB) are foundonly for the good candidates (row c). But apart from that,
the interpretation of the estimated distributions is compli-
cated by the substantial blurring caused by the measure-
ment error.
The goal of modeling is to eliminate the influence of
the measurement error, i.e., to recover the distribution
that would be obtained if hearing thresholds were deter-
mined with arbitrary accuracy. The result, represented
by the histograms in the left column of Figure 4, will be
referred to as the frequency distribution of the true
MTR (the model parameters are provided in Table 1; the
curves represent the function defined in Eq. (3)). A con-
volution of the theoretical distributions with the prob-
ability density function of the measurement error (curve
on the left of Figure 3) yields the curves in the middle
column, which agree reasonably well with the histo-
grams derived from the data. If cumulative frequency
distributions (right column) are considered instead of
frequency distributions, the agreement between model
and data appears to be almost perfect.
Comparing the three groups of patients is facilitated
when the differences in the number of cases are elimi-
nated by normalization. The cumulative distribution func-
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Figure 4 Comparison between data and model for three groups of patients: (a) all patients, (b) the poor candidates for the glycerol
test, and (c) the good candidates. Convolving the theoretical frequency distribution shown on the left with the probability density function of
the measurement error yields the observed frequency distribution shown in the middle (histogram representing the MTR values obtained from
the data, curve representing the model). The corresponding cumulative frequency distributions are shown on the right.
Table 1 Model parameters and area under the ROC curve
Model parameters Area under the ROC curve
N p0 θ (dB) assuming σ = 2.45 dB assuming σ = 1.2 dB
All patients 354 0.378 3.89 0.922 0.976
Poor candidates 229 0.377 2.71 0.889 0.963
Good candidates 125 0.244 5.67 0.949 0.983
Three groups of patients are considered (N is the number of group members). In the middle, the values of the two model parameters, p0 and θ, are provided. On
the right, the area under the ROC curve is given for two assumptions about the standard deviation of the measurement error.
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Figure 5 Cumulative distribution functions for the true MTR.
These functions were derived from the cumulative distribution
functions on the right of Figure 4 (which would be obtained in the
absence of measurement errors). The solid curve represents all
patients, whereas the other two curves represent the poor (dotted)






















Figure 6 False-positive rate (1 − specificity) versus true-positive
rate (sensitivity). The bold curve was obtained on the basis of all
patients, whereas the curves above and below were obtained for
the good and the poor candidates, respectively. Approximately
halving the standard deviation of the measurement error yielded
the dotted curves. By increasing the threshold of the assumed “gold
standard” method from 2 dB to 5 dB, the bold curve turned into the
curve bounding the gray area in the background.
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the true MTR (which would be observed in the absence of
measurement errors) does not exceed a specified value. If
all patients are considered (solid curve), no or almost no
effect (MTR ≤1 dB) is found in nearly every other case,
while this applies to only every third of the good candi-
dates (dashed curve). For the latter group, the cumulative
distribution function increases relatively slowly, which
contrasts with the steeper increase obtained for the poor
candidates (dotted curve). As a consequence of these
differences, the probability of finding an MTR of at most
5 dB (dotted vertical line) considerably varies for the three
groups.
ROC curves
The performance of a diagnostic test is commonly charac-
terized in terms of its specificity and sensitivity. If alterna-
tive versions of a method (or different methods) are to be
compared, these performance measures are conveniently
visualized in the so-called ROC space, where the horizon-
tal axis represents the false-positive rate (1 − specificity)
and the vertical axis represents the true-positive rate (syn-
onymous with sensitivity). The analysis evidently requires
that the test results can be checked against the actual facts
or the results of a superior method serving as the “gold
standard”. But this turns out to be problematic in the con-
text of Menière’s disease. A Monte Carlo simulation based
on the above modeling results offers at least a partial
workaround.To keep the simulation realistic, a “gold-standard”
method is assumed to signal a positive glycerol effect if
the true MTR exceeds a specified threshold (2 dB in
our simulations, unless stated otherwise). The assumption
of a threshold accounts for the fact that a distinction
between “no effect” and “almost no effect” is not only diffi-
cult to accomplish in reality, but may also be irrelevant
with respect to possible clinical consequences. After hav-
ing defined a “gold standard”, a ROC curve [30-32] is
easily derived from simulated data. The thick curve in
Figure 6 was obtained using the model parameters that
were determined on the basis of all patients, whereas the
curves above and below were obtained using the parame-
ters determined for the good and the poor candidates,
respectively (see Table 1). The measurement error had a
standard deviation of 2.45 dB, as estimated from our real
data.
A convenient summary measure for the performance
of a test is the area under the ROC curve (AUC). An
intuitive interpretation of the AUC is as follows: If a ran-
domly selected diseased individual is compared with a
randomly selected non-diseased individual, the AUC
corresponds to the probability that the test quantity (in
our case the MTR) is higher for the diseased individual
[33,34]. Random guessing would result in a ROC curve
corresponding to the diagonal line in Figure 6, which
has an AUC of 0.5. By contrast, an AUC greater than 0.9
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criterion is clearly fulfilled for the glycerol test, all the
more if only the good candidates are considered (AUC
values provided in Table 1). If methodological improve-
ments allowed us to approximately halve the standard
deviation of the measurement error (from 2.45 to 1.2 dB),
the three dotted curves would be obtained instead of the
three solid ones, and the AUC for the investigation of all
patients would increase from 0.922 to 0.976.
The threshold of the “gold-standard” method in the
above simulations (2 dB) corresponds to the lowest MTR
value that, according to the model presented in Figure 2b,
unequivocally represents a positive glycerol effect. But
with respect to future applications it is conceivable that
only patients showing stronger effects are considered good
candidates for a certain clinical measure. This would
require adjusting the criterion for a positive test result,
which in our model is achieved by increasing the thresh-
old of the “gold-standard” method. The curve bounding
the gray area in the background of Figure 6 corresponds
to the thick black curve (consideration of all patients), but
the threshold was 5 dB rather than 2 dB. The differences
between the two curves (the AUC increased from 0.922 to
0.960) have an obvious explanation: testing is the more
accurate the greater is the effect to be detected.
Discussion
Modeling the glycerol test data
Central to this study was the attempt to explain our
retrospective collection of glycerol test data [20] with a
simple model that distinguishes between true effect and
measurement error. The attempt turned out to be suc-
cessful in that a model was found by which the cumulative
frequency distribution of the observed MTR could be
reproduced almost perfectly. Nevertheless, as subsequent
considerations were based on the model rather than the
data, a critical reflection on the model appears to be ap-
propriate. The model builds on three main assumptions.
First, the true MTR and the measurement error are as-
sumed to be additive and statistically independent. Since
the measurement error essentially reflects methodological
imperfection and the patient’s uncertainty about the
threshold, this point is not considered to be critical.
Second, the measurement error is assumed to be nor-
mally distributed. Despite the minor problem revealed
in Figure 3, this assumption is considered acceptable as
well. A standard deviation of 2.45 dB for the mean of
five threshold reductions suggests that the standard de-
viation of a single threshold reduction is 2.45 ⋅ 51/2 =
5.48 dB. This value is consistent with the test-retest
variability of audiometric thresholds reported by others
[35-37]. Third, the probability density function of the
true MTR is postulated to correspond to the template
shown in Figure 2b. While the good agreement betweenmodel and data proves the suitability of this educated
guess, a more meticulous examination is indispensable.
When trying to deduce the probability density function
of the true MTR, it must be borne in mind that it is not
about finding the unique solution to a well-posed
problem. According to Eq. (1), the function sought,
g(x), is convolved with the probability density function
of the measurement error, h(x). The consequence is
that finer details of g(x) are smoothed out, making a
faithful reconstruction from the data impossible. This
is why we chose a parameterized model. The law of
parsimony, also known as Occam’s razor [38], man-
dates to make a model as simple as possible, and with
only two adjustable parameters our model complies
with this requirement. But still the problem remains
that many different two-parameter models could explain
the data equally well, for example the two models in
Figure 2. A disadvantage of the first one (Figure 2a) is that
the initial increase, from zero to the maximum, is an ex-
ample of a fine structure that is inevitably smoothed out
by the convolution with h(x). Moreover, the model sug-
gests that patients without a glycerol-induced threshold
reduction can be unequivocally distinguished from pa-
tients showing a rather small effect, which is, of course,
unrealistic. As such aspects may lead to misunderstand-
ings we switched to the model in Figure 2b. It is in the na-
ture of the problem that there are alternatives to this
second model, too. For example, one might consider
smoothing the sharp transition that occurs around 2 dB.
Questions of this kind become secondary, however, if the
focus is on the cumulative distribution of the true MTR,
because seemingly discrepant probability density functions
may be associated with nearly identical cumulative distri-
bution functions. Thus, given the fact that the model
explains the data so well, the curves in Figure 5 can be as-
sumed to provide a fairly realistic view of the cumulative
distribution of the true MTR, even though details of the
underlying probability density function are debatable.
Performance of the glycerol test and future prospects
After having found a model that accurately reproduces
the data, hitherto intractable questions could be addressed.
In particular, defining a virtual “gold standard” allowed us
to evaluate the performance of the glycerol test using ROC
analysis. Even in its present form, the test turned out to
have a “rather high accuracy” according to Swets’ [33]
classification of diagnostic techniques. Reducing the
standard deviation of the measurement error would fur-
ther enhance the performance, although it is difficult to
say how much improvement is realistically possible in a
clinical setting. At least there can be no doubt that the
current practice of determining thresholds of hearing in
steps of 5 dB sets a lower limit for the size of effects that
can be proven. Moreover, Figure 3 suggested that the
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threshold estimation techniques such as the recently pro-
posed single-interval adaptive procedure [39] could help
to significantly amend the test.
It shall be emphasized that the performance measures
examined in this study do not characterize the ability of
the glycerol test to fulfill what Klockhoff [19] considered
to be its genuine purpose: indicating endolymphatic
hydrops. Instead, they refer to the capability of the
audiometric procedure to detect a glycerol-induced
threshold reduction. Admittedly, the original reason
for configuring the analysis this way was a lack of reliable
information about the presence or absence of hydrops,
which necessitated finding a workaround. However, closer
inspection suggests that our solution is not at all a substi-
tute for a superior, albeit impracticable approach. This
realization is linked to the key question as to what the
actual purpose of the glycerol test is. Notwithstanding
the above-mentioned later view, Klockhoff and Lindblom
[40] took a positive glycerol test as evidence that hydro-
dynamic damping of the organ of Corti is reversible and
that treatment with diuretic drugs may be of value. Treat-
ment with diuretics is commonplace now, but strong evi-
dence to support their use in Menière patients is limited
[41]. Nevertheless, if not taken too literally, the initial idea
of Klockhoff and Lindblom may also guide future clinical
practice. What distinguishes the glycerol test from other
approaches is that it does not simply measure the conse-
quence of a pathophysiologic process, but probes to what
extent the patient’s current medical condition responds to
drug treatment, at least temporarily. Thus, the test could
help to estimate the chances of success of pharmacological
therapy [42,43]. Progress as to that may, consequently,
increase the interest in the glycerol test.
Diagnostic testing for Menière’s disease from a more
general perspective
Several other approaches have been proposed for diagnos-
ing Menière’s disease. Probably the most popular tech-
nique at present is electrocochleography: Endolymphatic
hydrops causes the summating potential (SP) to be en-
hanced compared to the compound action potential
(AP) of the auditory nerve, yielding an increased SP/AP
ratio [44]. However, opinions about the method are
divided: A recent survey among American otologists
and neurotologists showed that nearly half of the respon-
dents had stopped ordering electrocochleography due to
variability in results and lack of correlation with patients’
symptoms [45].
An abnormal endolymphatic pressure is supposed to
affect also the impedance of the middle ear transmission
system. However, testing for this effect by means of mul-
tifrequency tympanometry has only moderate diagnostic
accuracy [46]. Another option for diagnostic testing seemsto be the posture-induced phase shift of distortion-
product otoacoustic emissions monitored around 1 kHz
[47]. Auditory brainstem responses (ABR) have been
studied as well. High-pass noise masking appears to be
less efficient in patients with Menière’s disease [48].
Thus, these patients show ABR with abnormal latencies
if the masking level is adjusted to suit normal hearing
subjects [49]. The result of a traveling-wave-velocity test
was reported to be correlated with the outcome of
transtympanic electrocochleography [50].
The vestibular component of Menière’s disease can be
tested by recording the vestibular evoked myogenic poten-
tial (VEMP), which, in the case of a unilateral manifest-
ation of the disease, is of significantly lower amplitude on
the affected side [51]. VEMP abnormalities may enable
separation of Menière’s disease from other peripheral
vestibulopathies [52,53], although views differ as to
whether Menière’s disease can be distinguished from
vestibular migraine [54,55].
This glimpse on recent studies shows that various
possibilities are available to find objective correlates of
Menière’s disease. Even though most of these techniques
may not be suitable yet to provide reliable diagnostic in-
formation for individual patients, revealing statistical
differences between groups of patients and working out
the relationships between the different tests will help to
better understand the disease.
Fukuoka et al. [56] recently compared MRI, electroco-
chleography, and the glycerol test in 20 patients diag-
nosed with definite Menière’s disease. While the latter
two techniques yielded a positive result in only 11 and
12 patients, respectively, MRI gave evidence of hydrops
in 19 patients. The authors therefore concluded that
MRI is more useful for detecting hydrops than the two
functional tests. Even taken together, the two functional
tests were not competitive (only 15 patients showed a
positive result in at least one test). This does not surprise
considering that claims about the superiority of a combin-
ation of electrocochleography and glycerol test compared
to the single tests [57,58] are not well founded (false posi-
tives are left unconsidered).
Paradoxically, the seeming inferiority of the functional
tests could eventually prove to be an opportunity. Diag-
nostic testing is most useful when the presence of dis-
ease is neither very likely nor very unlikely [59], and
from this point of view, MRI is less informative than the
functional tests: If finding endolymphatic hydrops in a
patient diagnosed with definite Menière’s is rather likely,
actually testing for the hydrops is wasteful unless there
are compelling arguments to do so. Matters may be
different if hydrops is considered in a more nuanced
way, but attempts to derive a clinical benefit from this
perception failed as yet: MRI neither predicted the out-
come of intratympanic treatment with gentamicin [60,61]
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with betahistine [62]. While it is questionable at this point
whether any other presently available method would have
been more successful in this respect, the examples illus-
trate that there are clinically important questions which
imaging techniques may not be able to answer: A natural
limit is reached when functional aspects without an obvi-
ous morphological correlate are concerned.
Although the upsurge of imaging methodology could
eventually revolutionize the study of Menière’s disease,
the above consideration shows that there is no reason to
lose interest in functional methods. On the contrary,
increased efforts should be made to improve them. As
for the glycerol-induced change of state, it might be
worthwhile to consider not only the threshold of hearing
(classical glycerol test), but also other test quantities.
And indeed, this idea has already been pursued regard-
ing otoacoustic emissions [63], electrocochleography
[64], and VEMP [65]. The ability to make useful predic-
tions with respect to clinically important questions will
ultimately decide which method (or what combination
of methods) prevails. As to electrocochleography, it has
been suggested, for example, that a high SP/AP ratio at
the patient’s initial visit may be used as a predictor of
poor hearing outcomes [66]. Admittedly, even more use-
ful would be predictions about the chances of therapies
being considered. But, at present, that would perhaps be
asking too much, given that management of Menière’s
disease is a topic which itself requires more research.
Conclusions
The three key questions for decisions about using a
diagnostic test are how accurate the test is, how it adds
to the information provided by the history, examination
and other (cheaper or more readily available) tests, and
how it improves patient outcomes [13]. With regard to
the various approaches that have been proposed for
diagnosing Menière’s disease, these questions do not have
simple, uncontroversial answers. Since different methods
may target aspects of the disease that are not straightfor-
wardly linked, premature conclusions about the relative
merits of the various methods are to be avoided. This im-
plies that defining a particular method as the “gold stand-
ard” is problematic unless the goal of diagnostic testing is
clearly specified and the elected method is understood
well enough to assess its suitability for that purpose.
While in the past the main focus was on getting indirect
evidence of endolymphatic hydrops, MRI now provides
a direct approach. However, if patients diagnosed with
definite Menière’s disease almost always have endolym-
phatic hydrops, diagnostic testing with the goal to ac-
tually prove the hydrops may not be generally justified.
Instead, more attention should probably be paid to the
question as to what predictions can be made about thechances of specific therapies. The glycerol test (like similar
tests using other diuretics such as furosemide [67] or urea
[68,69]) has the extraordinary property that it does not
simply measure the consequence of a pathophysiologic
condition in the inner ear, but investigates whether this
condition is partially reversible. Even in its present, sub-
optimal form it fulfills Swets’ [33] criterion for tests of
“rather high accuracy”. As a positive outcome proves the
hearing loss to be partially reversible, the test could, pro-
spectively, help to predict whether a patient is a suitable
candidate for a certain type of therapy.
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